Bio-Path Holdings Inc (NASDAQ:BPTH) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totalling 207,200 shares, a decrease of 21.7% from the May 30th total of 264,600 shares. Based on an average daily volume of 331,500 shares, the days-to-cover ratio is currently 0.6 days. Currently, 12.1% of the shares of the stock are short sold.

An institutional investor recently bought a new position in Bio-Path stock. Virtu Financial LLC purchased a new stake in Bio-Path Holdings Inc (NASDAQ:BPTH) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,461 shares of the company’s stock, valued at approximately $336,000. Virtu Financial LLC owned about 0.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.77% of the company’s stock.

Shares of BPTH stock traded down $0.15 during trading hours on Thursday, hitting $12.95. The company’s stock had a trading volume of 38,400 shares, compared to its average volume of 2,033,690. The stock has a fifty day moving average of $13.68. Bio-Path has a twelve month low of $1.61 and a twelve month high of $73.52.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.89) EPS for the quarter.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Article: Short Selling Stocks and Day Traders

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.